Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
A Systematic Review and Meta-Analysis on the Association Between Lymphocyte Subsets and the Severity of Covid-19 Publisher



Dehghanbanadaki H1, 2 ; Aazami H3, 4 ; Shabani M5 ; Amighi D5 ; Seif F6 ; Dehnavi AZ5 ; Hajighadery A7 ; Nejad MMM7 ; Ghafouri M5 ; Hajizadeh N8 ; Abedin F5 ; Hajizadeh Z8 ; Heravi M9 ; Panahi P10 Show All Authors
Authors
  1. Dehghanbanadaki H1, 2
  2. Aazami H3, 4
  3. Shabani M5
  4. Amighi D5
  5. Seif F6
  6. Dehnavi AZ5
  7. Hajighadery A7
  8. Nejad MMM7
  9. Ghafouri M5
  10. Hajizadeh N8
  11. Abedin F5
  12. Hajizadeh Z8
  13. Heravi M9
  14. Panahi P10
  15. Kabir A11

Source: Immunopathologia Persa Published:2022


Abstract

Introduction: Prominent prognostic parameters that reflect the severity of coronavirus disease 2019 (COVID-19) to adopt an appropriate therapeutic approach are not fully identified. This systematic review and meta-analysis aimed to explore the association between lymphocyte variation and disease severity in COVID-19 individuals. Methods: We searched Web of Science, Scopus, PubMed, EMBASE and WHO website to retrieve studies investigating lymphocyte subset counts in non-severe and severe cases of COVID-19. The pooled standardized mean difference (SMD) between two groups and the pooled average count of each lymphocyte subset were assessed by employing a random-effect model. Results: Thirty-nine investigations on 5087 participants, including 3578 non-severe patients and 1509 severe patients, were included. The pooled analysis showed that non-severe patients had higher total T lymphocytes (SMD = 1.01; 95% CI: 0.82, 1.20; I2 = 75.7%), T helper cells (SMD = 1.07; 95% CI: 0.85, 1.28; I2 = 85.4%), T cytotoxic cells (SMD = 1.07; 95% CI: 0.82, 1.32; I2 = 87.1%), B cells (SMD = 0.72; 95% CI: 0.45, 0.98; I2 = 79.7%), and natural killer cells (SMD = 0.65; 95% CI: 0.47, 0.84; I2 = 63.1%) than severe patients and the average count of the corresponding lymphocyte signatures in non-severe patients/severe patients were 878.88/448.40, 493.12/268.96, 311.91/158.91, 177.09/110.37, and 155.02/103.09 cells/μL, respectively. Conclusion: Lymphopenia may be a dilemma in COVID-19 management because over-activation of lymphocytes may lead to cytokine storm or acute respiratory distress syndrome (ARDS). In contrast, lymphopenia may increase SARS-CoV-2 amplification and COVID-19 severity. Therefore, novel therapies targeting lymphocyte proliferation or contraction may counterbalance lymphocyte counts in these patients. © 2022 The Authors.
Other Related Docs
6. Novel Therapeutic Approaches for Treatment of Covid-19, Journal of Molecular Medicine (2020)
8. Advances in Immunotherapy for Covid-19: A Comprehensive Review, International Immunopharmacology (2021)
10. The Evaluation of Hematological Parameters and Their Correlation With Disease Prognosis in Covid-19 Disease in Iran, International Journal of Hematology-Oncology and Stem Cell Research (2023)
12. Immunosenescence and Inflamm-Ageing in Covid-19, Ageing Research Reviews (2023)